{
event: "article_read",
name: `Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients`,
author: ``,
tags: `Cardiovascular | Dyslipidemia | Dyslipidemia`,
publication_date: ``,
interaction_type: "content"
}
Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients
Watch the video and learn on how to leverage incremental clinical benefit to patients with recent ACS and LDL-C near 70 mg/dL from optimized statin therapy and PCSK9i.
.jpg/jcr:content/jcr_content%20(33).jpg)
Related articles
.jpg/jcr:content/jcr_content%20(36).jpg)
.png/jcr:content/jcr_content%20(1).png)
.png/jcr:content/jcr_content%20(47).png)
MAT-BH-2200017/v2/Jun 2023